RxDoctor Payments Data
★ My doctorsLook up a doctor →

James Parmele, MD

Interventional Pain Medicine · Maple Grove, MNNPI 1255545687

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,266 of the $12,831 with a category attached, or 64.4%. 19 manufacturers reported payments, led by Medtronic at 48.4% of the total. Reporting peaked in 2020 at $3,675 and has fallen 75.9% since, to $887 in 2025.

$12,831in general payments, 2019–2025

Across 194 payments — averaging $66.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Nevro Corp.$2K
  • Abbott$1K
  • Boston Scientific$1K
  • Saluda Medical Americas, Inc.$451
  • Biotronik NRO, Inc.$389
  • plus $894 from 13 others
$65,358in research payments, 2019–2025

Across 39 payments — averaging $1675.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nevro Corp.$60K
  • Globus Medical$5K

What the payments were for

  • Speaking & faculty fees$3,75029%
  • Travel & lodging$7756%
  • Food & beverage$8,26664%
  • Education$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)40$6,214
Nevro Corp.41$2,072
Abbott37$1,419
Boston Scientific24$1,392
Saluda Medical Americas, Inc.8$451
Biotronik NRO, Inc.15$389
Relievant Medsystems, Inc.5$266
Si-bone, Inc.3$173
SPR Therapeutics, Inc1$125
Vertos Medical, Inc.4$92
Teva Pharmaceuticals USA, Inc.5$71
Bioventus LLC2$39
Amgen2$32
Vertical Pharmaceuticals, LLC2$25
MML US, Inc.1$15
Ferring Pharmaceuticals Inc.1$15
Globus Medical1$15
Johnson & Johnson1$14
Collegium Pharmaceutical, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,831 in reported general payments places this provider in the 85th percentile of 26 interventional pain medicine providers in Minnesota.

See all interventional pain medicine providers in Minnesota →

Medicare billing

Part B allowed, 2024
$209,738
Medicare patients
578
Services billed
3,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin167$2,254
Lidocaine13$1,144
Tizanidine Hcl101$1,031
Topiramate71$742
Methocarbamol34$520
Baclofen32$474
Cyclobenzaprine Hcl26$417
Cephalexin39$290
Diclofenac Sodium12$251
Methylprednisolone33$217
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$191
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen43$176
Meloxicam32$136
Oxycodone Hcl12$18

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Maple Grove

See the full list for Minnesota →

Where these figures come from

Is this you, or does something look wrong? →